Search
FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products
… FDA has become aware of reports of adverse events involving compounded topical finasteride products potentially putting consumers at risk. … is no FDA-approved topical formulation of finasteride. Compounded topical finasteride products do not have …
MasterPharm, LLC. Issues Voluntary Nationwide Recall of Finasteride Plus 1.25mg Due to the Presence of an Undeclared Antihypertensive Drug
… MasterPharm, LLC. is voluntarily recalling 1 lot of Finasteride Plus 1.25mg, capsules to the consumer level. The Finasteride Plus capsules have been found to contain … water, dizziness and low blood pressure. The product is a compounded drug for hair loss and is packaged in orange …
Compounding Risk Alerts
… illnesses and deaths have been linked to poor quality compounded drugs. The agency works to identify and mitigate … professionals and compounders about risks associated with compounded drugs, including information on adverse events, … of potential risks associated with compounded topical finasteride products July 26, 2024 FDA alerts health care …
MasterPharm LLC - 612401 - 07/19/2021
… are implemented and, on July 2, 2020, voluntarily recalled compounded products within expiry that were prepared by … the Federal Food, Drug, and Cosmetic Act (FDCA). A. Compounded Drug Products Under the FDCA Section 503A of the … adverse events experienced by 74 patients associated with Finasteride Plus capsules produced by your firm that were …
July - September 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
… in August 2021 to include pancreatitis. Entyvio labeling Finasteride Plus 1.25mg capsules (compounded drug) Minoxidil (compounded drug) Cardiac effects related to undeclared or …
2023 Compounding Quality Center of Excellence Conference: Incident Management
Rx Unlimited Pharmacy, North Hills, CA. 483 Issued 10/21/2022
Hybrid Pharma LLC, Deerfield Beach, FL. 483 issued 09/03/2021
Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act